CATALYST PHARMACEUTICALS, INC. — Director's Dealing 2024

Jan 3, 2024

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2024-01-01

Reporting Person: Kalb Michael Wayne (Executive Vice President & CFO)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, par value $0.001 per share	0	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Options to purchase common stock	$16.81	2031-01-01	Common Stock (257214)		Direct
Restricted Stock Units	$		Common Stock (35693)		Direct

Footnotes

F1: Derivative Securities vest in five annual tranches beginning on January 1, 2025.

F2: Shares of common stock will be delivered to the Reporting Person upon vesting.

F3: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.